{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:10:15Z","timestamp":1793412615806,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neuropharm.2023.109504","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:20:02Z","timestamp":1678710002000},"page":"109504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders"],"prefix":"10.1016","volume":"231","author":[{"given":"Andreas B.","family":"Wulff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-9049","authenticated-orcid":false,"given":"Scott M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109504_bib1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109504_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","article-title":"Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells","volume":"36","author":"Aghajanian","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-8993(99)01224-X","article-title":"Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release","volume":"825","author":"Aghajanian","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109504_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0091-3057(99)00089-1","article-title":"Increasing the selectivity of drug discrimination procedures","volume":"64","author":"Appel","year":"1999","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109504_bib6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41386-019-0405-9","article-title":"The critical importance of basic animal research for neuropsychiatric disorders","volume":"44","author":"Bale","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib7","series-title":"New Research on Street Drugs","first-page":"167","article-title":"Natural source of drugs of abuse: magic mushrooms","author":"Ballesteros","year":"2006"},{"key":"10.1016\/j.neuropharm.2023.109504_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109504_bib9","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109504_bib10","doi-asserted-by":"crossref","first-page":"9870","DOI":"10.1073\/pnas.0700436104","article-title":"Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex","volume":"104","author":"B\u00e9\u00efque","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109504_bib11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00213-004-2108-z","article-title":"Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl\/6J mice","volume":"179","author":"Benneyworth","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109504_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1460-9568.2002.02072.x","article-title":"Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons","volume":"16","author":"Bickmeyer","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nn.3355","article-title":"Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression","volume":"16","author":"Cai","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","article-title":"5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines","volume":"14","author":"Cameron","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109504_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109504_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109504_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis","volume":"39","author":"Carhart-Harris","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2023.109504_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109504_bib23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41386-019-0540-3","article-title":"Prophylactic efficacy of 5-HT4R agonists against stress","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1139\/jpn.0852","article-title":"Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system","volume":"33","author":"Chenu","year":"2008","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","article-title":"Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis","volume":"238","author":"Conley","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109504_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00401509","article-title":"A possible correlation between drug-induced hallucinations in man and a behavioural response in mice","volume":"11","author":"Corne","year":"1967","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2023.109504_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","article-title":"Pharmacological mechanism of the non-hallucinogenic 5-HT2A agonist ariadne and analogs","volume":"14","author":"Cunningham","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.neuroscience.2007.04.045","article-title":"Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression","volume":"147","author":"de Foubert","year":"2007","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2023.109504_bib30","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41386-022-01301-9","article-title":"Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline","volume":"47","author":"de Gregorio","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib31","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1021\/acschemneuro.2c00170","article-title":"Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT2A receptor agonists in mice","volume":"13","author":"de la Fuente Revenga","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","author":"de la Fuente Revenga","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109504_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02246053","article-title":"Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5-HT1A receptor antagonists","volume":"119","author":"Detke","year":"1995","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109504_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nm.4246","article-title":"Resting-state connectivity biomarkers define neurophysiological subtypes of depression","volume":"23","author":"Drysdale","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109504_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/syn.21940","article-title":"Gene expression related to serotonergic and glutamatergic neurotransmission is altered in the flinders sensitive line rat model of depression: effect of ketamine","volume":"71","author":"Du Jardin","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2023.109504_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109504_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113612","article-title":"Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response","volume":"154","author":"Erkizia-Santamar\u00eda","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2023.109504_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/acsptsci.0c00063","article-title":"Structure-activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore","volume":"4","author":"Flanagan","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.neuropharm.2023.109504_bib40","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.neuropharm.2007.03.013","article-title":"Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane","volume":"52","author":"Garcia","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acsptsci.2c00177","article-title":"Structure-activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice","volume":"5","author":"Glatfelter","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.neuropharm.2023.109504_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109504_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109504_bib45","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","article-title":"Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex","volume":"23","author":"Gonz\u00e1lez-Maeso","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib46","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109504_bib47","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjp.2008.207","article-title":"Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK","volume":"154","author":"Green","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/7854_2016_466","article-title":"Effect of hallucinogens on unconditioned behavior","volume":"36","author":"Halberstadt","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2023.109504_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1526-4610.1977.hed1702054.x","article-title":"Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide","volume":"17","author":"Herrmann","year":"1977","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2023.109504_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109504_bib56","doi-asserted-by":"crossref","DOI":"10.1089\/psymed.2022.0012","volume":"1","author":"Hibicke","year":"2023","journal-title":"Psychedelic Medicine"},{"key":"10.1016\/j.neuropharm.2023.109504_bib57","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.640241","article-title":"Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property","volume":"12","author":"Higgins","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF02160424","article-title":"Konstitutionsaufkl\u00e4rung und synthese von psilocybin","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2023.109504_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02159243","article-title":"Psilocybin, ein psychotroper wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim","volume":"14","author":"Hofmann","year":"1958","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2023.109504_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02166696","article-title":"Identifizierung von psilocin","volume":"15","author":"Hofmann","year":"1959","journal-title":"Experientia"},{"key":"10.1016\/j.neuropharm.2023.109504_bib62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3181\/00379727-106-26228","article-title":"Dephosphorylation of psilocybin to psilocin by alkaline phosphatase","volume":"106","author":"Horita","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.neuropharm.2023.109504_bib63","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0269881120959614","article-title":"Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin","volume":"35","author":"Jefsen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/neu.2019.15","article-title":"Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat","volume":"31","author":"Jefsen","year":"2019","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib65","doi-asserted-by":"crossref","first-page":"19575","DOI":"10.1073\/pnas.0905884106","article-title":"Rapid modulation of spine morphology by the5-HT2A serotonin receptor through kalirin-7 signaling","volume":"106","author":"Jones","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2023.109504_bib66","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41586-022-05258-z","article-title":"Bespoke library docking for 5-HT2Areceptor agonists with antidepressant activity","volume":"610","author":"Kaplan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109504_bib67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1074\/mcp.M113.036558","article-title":"Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists","volume":"13","author":"Karaki","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.neuropharm.2023.109504_bib68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2019.55.7.2958474","article-title":"Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties","volume":"55","author":"Kaur Gill","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.neuropharm.2023.109504_bib69","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1017\/S0033291713002857","article-title":"Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis","volume":"44","author":"Kishi","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109504_bib70","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(24)37788-2","article-title":"F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential","volume":"287","author":"Koek","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109504_bib71","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0706679105","article-title":"Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy","volume":"105","author":"Liu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109504_bib73","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.neuron.2007.07.041","article-title":"Serotonin4 (5-HT4) receptor agonists are putative antidepressants with a rapid onset of action","volume":"55","author":"Lucas","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109504_bib74","first-page":"24","article-title":"Behavioral studies of serotonin receptor agonists as antidepressant drugs","volume":"52","author":"Lucki","year":"1991","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109504_bib75","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109504_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","article-title":"Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience","volume":"50","author":"Madsen","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109504_bib77","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1523\/JNEUROSCI.20-24-09104.2000","article-title":"Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus","volume":"20","author":"Malberg","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib78","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0022-3565(25)20792-3","article-title":"LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex","volume":"278","author":"Marek","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109504_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-002-1141-z","article-title":"Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats","volume":"164","author":"Marona-Lewicka","year":"2002","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ebiom.2016.08.049","article-title":"Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain","volume":"11","author":"Martin","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neuropharm.2023.109504_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109504_bib82","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2399","article-title":"Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism","volume":"7","author":"Meinhardt","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuropharm.2023.109504_bib84","first-page":"6","article-title":"The psychiatric pipeline: 10 agents to watch","volume":"38","author":"Miller","year":"2021","journal-title":"Psychiatr. Times"},{"key":"10.1016\/j.neuropharm.2023.109504_bib85","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1460-9568.2006.04949.x","article-title":"5-HT4 receptor activation induces long-lasting EPSP-spike potentiation in CA1 pyramidal neurons","volume":"24","author":"Mlinar","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","article-title":"Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists","volume":"493","author":"Moreno","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109504_bib87","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib88","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109504_bib89","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00213-011-2297-1","article-title":"The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration","volume":"217","author":"Nikiforuk","year":"2011","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.113093","article-title":"Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice","volume":"401","author":"Odland","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109504_bib91","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.122.000590","article-title":"Animal behavior in psychedelic research","author":"Odland","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109504_bib92","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev-neuro-110920-040422","article-title":"Synaptic mechanisms regulating mood state transitions in depression","volume":"45","author":"Parekh","year":"2022","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fphar.2015.00200","article-title":"5-HT6 receptor agonism facilitates emotional learning","volume":"6","author":"Pereira","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib95","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1176\/appi.ajp.20220423","article-title":"Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation?","volume":"179","author":"Pizzagalli","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib96","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib97","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2017.97","article-title":"Data-driven subgroups in depression derived from directed functional connectivity paths at rest","volume":"42","author":"Price","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib98","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0091-3057(01)00720-1","article-title":"5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens","volume":"72","author":"Rabin","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109504_bib99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.14348\/molcells.2017.0080","article-title":"5-Hydroxytryptamine 6 receptor (5-HT6R)-mediated morphological changes via RhoA-dependent pathways","volume":"40","author":"Rahman","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuropharm.2023.109504_bib100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/ijms22020835","article-title":"A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain","volume":"22","author":"Raval","year":"2021","journal-title":"Int J Mol Sciences"},{"key":"10.1016\/j.neuropharm.2023.109504_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96736-3","article-title":"LSD-stimulated behaviors in mice require \u03b2-arrestin 2 but not \u03b2-arrestin 1","volume":"11","author":"Rodriguiz","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109504_bib102","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib103","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fnhum.2014.00204","article-title":"The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers","volume":"8","author":"Roseman","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib104","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry and the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146375","article-title":"5-HT6receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801","volume":"1722","author":"Rychtyk","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109504_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainres.2007.12.032","article-title":"Neuroprotective effects of serotonin 5-HT 1A receptor activation against ischemic cell damage in gerbil hippocampus: involvement of NMDA receptor NR1 subunit and BDNF","volume":"1199","author":"Salazar-Colocho","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109504_bib107","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","article-title":"Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109504_bib108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT(1A) receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib109","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41573-022-00552-x","article-title":"Predictive validity in drug discovery: what it is, why it matters and how to improve it","volume":"21","author":"Scannell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109504_bib110","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1476-5381.1992.tb09047.x","article-title":"Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive\/antidepressant-like actions in rodents","volume":"105","author":"Schlicker","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib111","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109504_bib112","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1002\/hbm.22562","article-title":"Enhanced repertoire of brain dynamical states during the psychedelic experience","volume":"35","author":"Tagliazucchi","year":"2014","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2023.109504_bib113","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1152\/jn.1993.69.5.1749","article-title":"Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex","volume":"69","author":"Tanaka","year":"1993","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109504_bib114","article-title":"Plasticity of synapses and reward circuit function in the genesis and treatment of depression","author":"Thompson","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109504_bib115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tins.2015.03.003","article-title":"An excitatory synapse hypothesis of depression","volume":"38","author":"Thompson","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaw3122","article-title":"Interclass GPCR heteromerization affects localization and trafficking","volume":"13","author":"Toneatti","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuropharm.2023.109504_bib117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib118","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109504_bib119","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2023.109504_bib120","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neuropharm.2023.109504_bib121","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1126\/science.7071600","article-title":"Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions","volume":"216","author":"White","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109504_bib122","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.pbb.2007.06.003","article-title":"Psilocybin-induced stimulus control in the rat","volume":"87","author":"Winter","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109504_bib123","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","article-title":"Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders","volume":"25","author":"Wittenberg","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109504_bib124","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.3390\/ijms23126713","article-title":"Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior","volume":"23","author":"Wojtas","year":"2022","journal-title":"Int J Mol Sciences"},{"key":"10.1016\/j.neuropharm.2023.109504_bib125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0006-8993(90)90778-A","article-title":"Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons","volume":"531","author":"Woolley","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109504_bib126","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.neuropharm.2023.109504_bib127","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:23:58Z","timestamp":1758439438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":126,"alternative-id":["S0028390823000941"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109504","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109504"}}